Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (154)
  • Open Access


    MiR-145-5p Suppresses Hepatocellular Carcinoma Progression by Targeting ABHD17C

    Linpei Wang1,#, Xiaoqiu Ma2,#, Youqi Chen1, Jiahui Zhang1, Jiawei Zhang1, Wei Wang1,*, Shaojian Chen3,*

    Oncologie, Vol.24, No.4, pp. 897-912, 2022, DOI:10.32604/oncologie.2022.025693

    Abstract Background: MicroRNA-145-5p (miR-145-5p) reportedly inhibits hepatocellular carcinoma (HCC) by targeting ARF6, SPATS2, CDCA3, KLF5, and NRAS, indicating that miR-145-5p plays an important role in the occurrence and development of HCC by regulating the expression of various genes. In this study, we aimed to explore novel downstream targets of miR-145-5p and elucidate the potential mechanism of miR-145-5p in HCC. Materials and Methods: A bioinformatics analysis was performed to determine the clinical significance of miR-145-5p and alpha/beta hydrolase domain-containing protein 17C (ABHD17C) in patients with HCC. The ability of Hep3B cells to proliferate, migrate, and invade was examined after overexpression of miR-145-5p… More >

  • Open Access


    Research on Clinical Effectiveness of Aspirin for Treating Breast Cancer and Cell Protein Biomarkers on Aspirin Treatment in Drug-Resistant Estrogen Receptor-Positive Breast Cancer Cells

    Junwei Cui1, Minghua Li2, Ruifang Pang2,*, Yinhua Liu1,*

    Oncologie, Vol.24, No.4, pp. 743-768, 2022, DOI:10.32604/oncologie.2022.025419

    Abstract Background: Aspirin (ASA) has been reported to have an antitumor effect but the role of ASA in the prevention and treatment of breast cancer (BC) is still controversial. This study aimed to identify clinical effectiveness of ASA in the treatment of BC and explore the antitumor target proteins of ASA that may be involved in overcoming tamoxifen resistance in estrogen receptor (ER)-positive BC cells. Materials and Methods: Randomized controlled trials (RCTs) of ASA in the treatment of BC were queried from the databases, including PubMed, Web of Science, Cochrane Library, WanFang, and Chinese National Knowledge Infrastructure. According to the quality… More >

  • Open Access


    Study on the Value of Ultrasound Elastography Combined with Plasma miRNA Expression in the Early Detection of Breast Cancer

    Qian Zhang1,2,#, Yuanyuan Cao2,#, Mingming Fang3, Qin Yang2, Pingyang Zhang1,*

    Oncologie, Vol.24, No.4, pp. 717-727, 2022, DOI:10.32604/oncologie.2022.026998

    Abstract Background: Breast cancer (BC) is the most common malignant tumor in women, and its morbidity and mortality are increasing each year, due to the lack of specific clinical symptoms in the early stage of BC, and the lack of diagnostic methods for early breast cancer. Therefore, identifying an effective diagnostic method for early BC has become urgent. Materials and Methods: Breast lesions with a histological diagnosis that were examined by ultrasonic elastography (UE) in our department from June 2020 to December 2021 were reviewed. qRT-PCR was performed to measure the expression levels of miR-144-5p and miR-26b-5p in the plasma of… More >

  • Open Access


    The Neurosurgical Challenge of Primary Central Nervous System Lymphoma Diagnosis: A Multimodal Intraoperative Imaging Approach to Overcome Frameless Neuronavigated Biopsy Sampling Errors

    Roberto Altieri1,2,*, Francesco Certo1, Marco Garozzo1, Giacomo Cammarata1, Massimiliano Maione1, Giuseppa Fiumanò3, Giuseppe Broggi4, Giada Maria Vecchio4, Rosario Caltabiano4, Gaetano Magro4, Giuseppe Barbagallo1

    Oncologie, Vol.24, No.4, pp. 693-706, 2022, DOI:10.32604/oncologie.2022.025393

    Abstract Background: Intracranial lymphoma remains a challenging differential diagnosis in daily neurosurgical practice. We analyzed our early experience with a surgical series of frameless neuronavigated biopsies in Primary CNS Lymphomas (PCNSLs), highlighting the importance of using an intraoperative combined imaging protocol (5-ALA fluorescence, i-CT and 11C-MET-PET) to overcome potential targeting errors secondary to tumor volume reduction after corticosteroid therapy. Materials and Methods: All patients treated for PCNLSs at our center in a 24-month period (1/1/2019 to 31/12/2020) were analyzed. Our cohort included 6 patients (4 males), with a median age of 67 years (59–82). A total of 45 samples were evaluated… More >

  • Open Access


    Angiogenic Gene PTK2 is a Potential Biomarker of Gestational Diabetes Mellitus and is Significantly Associated with Breast Cancer Immune Infiltration

    Xuelian Du1,#, Hao Shi2,#, Haiyan Liu1, Linghua Zhou1, Anqun Xie1, Jufang Guo1,*

    Oncologie, Vol.24, No.4, pp. 769-787, 2022, DOI:10.32604/oncologie.2022.026248

    Abstract Background: Gestational diabetes mellitus (GDM) affects the health of numerous women around the world. A recent study has shown that GDM is associated with an increased incidence of cancer. In this study, we aimed to explore the possible shared mechanisms and potential common therapeutic targets between GDM and cancer. Methods: The limma package was used to identify differentially expressed genes (DEGs) in GDM. The Cytoscape plugin cytoHubba was used to screen hub genes. The CIBERSORT algorithm was used to explore the correlation between hub genes and immunity. Cox regression analysis was used to assess the relationship between protein tyrosine kinase… More >

  • Open Access


    The Emerging Role of Lymphocyte Activation Gene 3 in the Cancer Immunotherapy

    Xue Cui1,2, Min Peng2, Honglei Chen1,*

    Oncologie, Vol.24, No.4, pp. 665-678, 2022, DOI:10.32604/oncologie.2022.023641

    Abstract The emergence of tumor immunotherapy, especially immune checkpoint inhibitors (ICIs), has brought new life to cancer treatment, and ICIs can effectively treat various tumors. Among the immune anti-cancer therapies, PD-1 is undoubtedly the hot target after CTLA-4, but due to the ineffectiveness of PD-1 in treating certain tumors, researchers have shifted their focus to other combination targets, such as LAG-3, TIM3, IDO-1, etc. One of these promising targets is LAG-3, a target with multiple clinical trials, which has increasingly shown to be an inhibitory co-receptor that plays a vital role in autoimmunity, cancer immunity, and anti-infection immunity. Immune combination therapy… More >

  • Open Access


    Racial Disparities in Clinical Features and Survival Outcomes among Patients with Pancreatic Neuroendocrine Tumor: A Contemporary SEER Database Analysis

    Fei Wang1, Jihyun Ma2, Nan Zhao3, Chi Lin3,*, Haixing Jiang1,*

    Oncologie, Vol.24, No.4, pp. 865-895, 2022, DOI:10.32604/oncologie.2022.025447

    Abstract Objective: The characteristics of clinical features and prognoses among patients with different racial backgrounds have not been clearly studied. We thus investigated the clinical characteristics and overall survival (OS) differences among Asian, White, and Black patients with pancreatic neuroendocrine tumors (pNETs). Materials and Methods: The Surveillance, Epidemiology, and End Results (SEER) database was queried to identify patients with pNETs between 1983 and 2015. We performed univariable (UVA) and multivariable logistic regression (MVA) to assess the association between variables and race category. A Kaplan-Meier (KM) plot was used to calculate the OS rates. The Cox proportional hazard regression was used to… More >

  • Open Access


    RCN3 Expression Indicates Prognosis in Colorectal Cancers

    Shengzhe Ma1,#, Xiaoming Zhu1,#, Cheng Xin1,#, Fuao Cao1, Mengnan Xu1, Xiangling Han1, Jinke Sui3,*, Wenjun Chang2,*, Wei Zhang1,*

    Oncologie, Vol.24, No.4, pp. 823-833, 2022, DOI:10.32604/oncologie.2022.025411

    Abstract Background: Reticulocalbin 3 (RCN3) has been associated with several malignancies. However, its role in colorectal cancer (CRC) remains controversial. Thus, this study aimed to investigate the role of RCN3 in CRC prognosis. Methods: The clinical significance of RCN3 expression in CRC was evaluated in a large cohort of 483 patients. Normal tissues, carcinoma, para-carcinoma, adenoma, and metastatic tissues were evaluated by immunohistochemistry. We investigated the association between RCN3 expression and CRC occurrence in tumors and other tissues. Prognostic factors were also evaluated by Kaplan-Meier survival analysis and the Cox regression model. Results: RCN3 was significantly overexpressed in CRC and metastatic… More >

  • Open Access


    PD-1 Relevant Genes Predict the Prognosis of Breast Cancer and Their Prediction Effect in Tumor Response to Immunotherapy

    Yu Xiao1,2,#, Jianping Jiang3,#, Yan Chen1,4, Yi Huang1, Changyuan Wei1,*

    Oncologie, Vol.24, No.4, pp. 729-742, 2022, DOI:10.32604/oncologie.2022.026118

    Abstract Background: Immunotherapy is becoming a powerful approach in the treatment of breast cancer. However, high response rates in the majority of breast cancer patients have yet to be achieved. Materials and Methods: Based on public data sources, we identified 22 genes that are correlated with PD-1 expression as well as differentially expressed between tumor tissues and normal tissues, and high expression of all the key genes was correlated with a superior survival outcome. Using the least absolute shrinkage and selection operator Cox regression model, a risk score was constructed. Results: A multivariate Cox analysis showed that the constructed risk score… More >

  • Open Access


    Impact of Complementary Medicines on Survival in Patients with Cancer Treated with Oral Chemotherapy in an Oncology Hospital in France: Exploratory Study

    Impact des Thérapies Complémentaires sur la Survie de Patients Atteints d’un Cancer Traités par Chimiothérapie Orale dans un Établissement Hospitalier Français Spécialisé en Oncologie : Étude Exploratoire

    Grégory Ninot1,2,*, Estelle Guerdoux1,2, François Carbonnel1, Kerstin Faravel2, Ludovic Ismael1, Fanny Leenhardt2, Béatrice Lognos1, Caroline Perrier2, Laurent Philibert2, Boris Tronc1, Marie Viala2

    Oncologie, Vol.24, No.4, pp. 605-612, 2022, DOI:10.32604/oncologie.2022.024558

    Abstract A retrospective observational study carried out in the United States showed a decrease in survival in patients treated for breast, prostate, lung and colorectal cancer with complementary medicines. We verified this result with a French population of consecutive 636 patients diagnosed with the same cancer and treated with oral chemotherapy in an hospital for three years. An interview by a pharmacist before the administration of oral chemotherapy was made to identify the complementary medicines used by the patients. We compared the overall survival using a log-rank test by stratifying the groups (number of cancers, number of comorbidities, age, sex). The… More >

Displaying 11-20 on page 2 of 154. Per Page  

Share Link